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Abstract 
 
Objective: ZNF750, a transcriptional regulator of epidermal differentiation, has been 
identified as a tumor suppressor in esophageal squamous cell carcinoma (ESCC). The 
aim of the present study was to investigate the clinical and prognostic significance of 
ZNF750 expression and evaluate the effect of ZNF750 knockdown on cell proliferation, 
migration, invasion, and apoptosis in ESCC.  
Methods: A total of 124 patients with ESCC who underwent curative esophagectomy were 
evaluated to investigate the clinical and prognostic significance. The expression of 
ZNF750 in surgical specimens was immunohistochemically assessed and used in the 
analysis of clinicopathological features and the overall survival (OS). Furthermore, 
eighty-seven patients who underwent neoadjuvant chemoradiotherapy (CRT), followed 
by curative esophagectomy were evaluated to investigate the relationship between the 
ZNF750 expression and CRT response. The expression of ZNF750 in pre-treatment 
biopsy samples was immunohistochemically investigated and compared to the 
histopathological effectiveness of CRT in surgical specimens. The molecular role of 
ZNF750 was investigated by ZNF750 knockdown using small interfering RNA (siRNA) 
in ESCC cell lines.  
Results: Low ZNF750 expression had a significant correlation with positive lymph node 
metastasis (P = 0.028). Furthermore, there was a significant relationship between low 
expression of ZNF750 in ESCC and a poor OS, and a multivariate analysis showed that 
low ZNF750 expression was an independent prognostic factor (P = 0.020). In addition, 
the high expression of ZNF750 was closely correlated with good sensitivity to CRT (P = 
0.016). A univariate analysis showed that the high/intermediate expression of ZNF750 
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was a significant predictive factor for good CRT sensitivity (P = 0.006). The 
high/intermediate expression of ZNF750 (30% or more) remained an independent 
predictive factor for sensitivity to CRT in a multivariate analysis (P = 0.033). The cell 
growth, migration, and invasion were significantly increased, and the cell apoptosis was 
significantly decreased by down-regulation of ZNF750.  
Conclusions: The low expression of ZNF750 was significantly associated with a poor 
prognosis and a low sensitivity to CRT, and ZNF750 expression may therefore be a 
reliable prognostic biomarker and a candidate biomarker for predicting the effectiveness 
of CRT in ESCC.  
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Introduction 
 
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive types of 
gastrointestinal cancers. In recent decades, combination therapy of surgery, 
chemotherapy, and radiotherapy has been developed, and the outcome of ESCC has 
improved [1, 2]. However, the prognosis of ESCC is still not desirable [3, 4]; therefore, 
elucidation of the mechanism underlying the progression of this cancer and the 
identification of specific molecular markers predicting the prognosis are significant 
issues regarding the effective management and improvement of the prognosis of ESCC. 
In addition, while chemoradiotherapy (CRT) is quite effective in a certain population of 
patients with ESCC, the development of CRT resistance remains a major obstacle to 
improving the outcomes of patients with this form of cancer. Furthermore, in some 
patients, CRT induces severe adverse events, such as pneumonitis, cardiomyositis and 
uncontrollable pulmonary effusion, and measures to avoid these adverse events are 
urgently needed. For these reasons, accurate patient selection and the prediction of the 
CRT response before treatment are key strategies in the treatment of ESCC.  
 
Recently, cancer genome research has been extensively conducted for the development 
of individualized medical treatment. It is therefore necessary to clarify the function and 
examine the clinicopathological significance of cancer-related genes discovered by 
genome analyses. ZNF750, the gene responsible for eborrhea-like dermatitis with 
psoriasiform elements, is a remarkable gene shown to have a relationship with ESCC by 
several whole-exome sequencing studies. This gene is significantly mutated at a 
frequency of 6%-16.7% [5-8]. ZNF750 was reported to act as a transcriptional regulator 
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of epidermal differentiation, and the expression of ZNF750 induces epidermal 
differentiation genes and suppresses epidermal progenitor genes [9]. ZNF750 has been 
shown to function as a tumor suppressor [5, 6, 10], and we therefore consider ZNF750 
to be a notable gene in the field of ESCC. However, no reports have described the 
clinicopathological features, prognostic value of ZNF750 expression, and the 
correlation between the ZNF750 expression and sensitivity to CRT in ESCC. 
 
Therefore, in this study, we investigated ZNF750 expression in ESCC using 
immunohistochemical staining. In addition, we divided the subjects into two groups 
based on their expression level and compared the clinical factors and survival period 
between the groups. Furthermore, we investigated the ZNF750 expression in pre-
treatment biopsy specimens and determined the effectiveness of CRT in surgically 
resected specimens to evaluate the correlation between the ZNF750 expression and 
sensitivity to CRT in ESCC. 
We also investigated the molecular role of ZNF750 using human ESCC cell lines. 
 
Materials and Methods 
 
Clinical specimens and cell culture 
 
Primary ESCC specimens were obtained from 124 patients with pathologically diagnosed 
ESCC at Chiba University Hospital from 1997 to 2010. All patients underwent radical 
surgery with three-region lymph node dissection (neck, chest, and abdomen). Patients 
who received any other preoperative treatments or whose pathological diagnosis was not 
ESCC were excluded from the present study. The staging classification was assessed 
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using the TNM system (UICC 7th edition) [11]. The patient characteristics are shown in 
Table 1. Written informed consent was obtained from all of the patients for research 
purposes. 
 
Table 1. Patient characteristics N=124 
Age (minimum-maximum) 64 (40-84) 
Sex (male:female) 103:21 
Pathological T factor   
  Tis/T1/T2/T3/T4 1/53/13/49/8 
Pathological N factor  
  N0/N1 62/62 
Stage   
  0/I/II/III/IV 1/33/41/41/8 
Tumor differentiation  
  Well/Moderate/Poor 33/70/21 
 
Pre-treatment biopsy specimens were obtained from 87 patients who received a 
pathological diagnosis of ESCC at our department between 2000 and 2015. All patients 
received neoadjuvant CRT with 5-fluorouracil (5-FU) and cisplatin (CDDP) followed 
by curative esophagectomy. The dose and schedule of the anticancer drugs and 
radiotherapy were in line with a previous report [12]. Patients who received any other 
preoperative treatments (with the exception of neoadjuvant CRT) and patients who did 
not receive a pathological diagnosis of ESCC were excluded from this study. Staging 
was performed using the TNM system (UICC 7th edition) [11]. The patient’s 
characteristics are recorded in Table 2. 
 
Table 2. Patient characteristics  
Age (minimum-maximum) 64.1 ± 6.4 (44-78) 
Gender (male:female) 77:11 
Tumor location   
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  Ce/Ut/Mt/Lt/Ae 5/17/46/18/1 
Tumor depth   
  T1/T2/T3/T4 4/4/39/40 
Tumor size (cm) 6.5 ± 2.6 
Lymph node metastasis   
  N0/N1 6/81 
Stage   
  I/II/III/IV 1/7/72/7 
Tumor differentiation  
  Well/Moderate/Poor 6/46/22 
Total dose of radiation (Gy) 41.4 ± 6.3 
  5-FU (mg) 3940 ± 645 
  CDDP (mg) 109 ± 23 
Adverse events of CRT  
  Yes/No 22/48 
Pathological effectiveness of CRT (%)  
  Grade 3 15 (17.3) 
  Grade 2 41 (47.1) 
  Grades 1 and 0 31 (35.6) 
 
The TE8 and TE11 human ESCC cell lines were used in this study. Both cell lines were 
obtained from Cell Resource Center for Biomedical Research Institute of Development, 
Aging and Center, Tohoku University, Japan. The cells were grown in Dulbecco’s 
Modified Eagle’s medium (DMEM; Life Technologies, Grand Island, NY, USA) 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin sodium, and 100 
μg/ml streptomycin in a humidified atmosphere containing 5% CO2 at 37 °C. 
 
Immunohistochemistry 
 
The expression of ZNF750 was immunohistochemically investigated using the 
peroxidase-antiperoxidase complex method. The sectioned specimens were 
deparaffinized, and incubated with Target Retrieval Solution (S2031; DAKO Japan, 
Tokyo, Japan) at 95 °C for 40 minutes. The endogenous peroxidase activity was blocked 
by methanol with 3% hydrogen peroxide at room temperature for 20 minutes. The 
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sectioned specimens were then incubated with the primary anti-human ZNF750 
polyclonal antibody (HPA021573; Sigma-Aldrich, St. Louis, MO, USA) at 4°C for 18 h 
at a dilution of 1:200 (S0809; DAKO Japan). After several washes with tris-buffered 
saline, the sectioned specimens were incubated with the secondary antibody (En 
Vision/HRP, anti-mouse/rabbit, K5001; DAKO Japan) at 37°C for 60 minutes. After 
several washes, the sectioned specimens were treated with 3,3’-diaminobenzidine 
(S3468; DAKO Japan) for 2 minutes. They were then counterstained with hematoxylin. 
Finally, the sectioned specimens were dehydrated with ethanol and mounted. 
 
The evaluation of ZNF750 immunohistochemical staining for surgical specimens 
 
After ZNF750 immunohistochemical staining, patients were divided into two groups as 
follows: The proportion of positive-stained cells was scored as 1 point (0-29%), 2 points 
(30-59), or 3 points (>60%). The staining intensity was scored as 0 points (no staining), 
1 point (weak), 2 points (moderate), or 3 points (strong). The total score was calculated 
by adding the proportion score and the intensity score. A total score of ≥3 was defined as 
high expression, and <3 was defined as low expression. 
The ZNF750 expression was used in the analysis of the clinicopathological features and 
the overall survival (OS). Representative images of ZNF750 expression are shown in 
Figure 1. All specimens were assessed by two different observers independently. 
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Figure 1. Images for high expression (a and c) and low expression (b and d) are shown 
(× 100 in the upper section, × 400 in the lower section). 
 
The evaluation of ZNF750 immunohistochemical staining for pre-treatment biopsy 
specimens 
 
The results of ZNF750 immunohistochemical staining were evaluated based on the 
percentage of cells that was stained in a ×100 magnification field, as follows: low 
expression, 0–29%; intermediate expression, 30–59%; and high expression, 60–100%. 
The ZNF750 expression was compared with the clinicopathological features. 
Representative images of the ZNF750 expression are shown in Figure 2. Two different 
observers assessed the expression of ZNF750 independently. 
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Figure 2. Representative images of ZNF750 expression (from different cases) 
demonstrating low expression (left), intermediate expression (middle) and high 
expression (right). 
 
The Pathological Evaluation of the Efficacy of CRT 
 
The histopathological efficacy of the treatment was assessed using the pathological 
criteria for the assessment of the effectiveness of radiotherapy and chemotherapy based 
on the Japanese classification of esophageal cancer (11th edition) [13, 14]. This criteria 
were as follows: grade 0 indicates an ineffective treatment with no cytological or 
histological therapeutic efficacy; grade 1 indicates a slightly effective therapy, when 
≥1/3 of the tumor tissue is composed of viable cancer cells (some evidence of degeneracy 
of cancer tissue or cells is recognized); grade 2 indicates a moderately effective 
treatment, when <1/3 of the tumor tissue is composed of viable cancer cells (severe 
degeneracy or necrosis is recognized in other cancer cells); and grade 3 indicates a 
markedly effective treatment, when there is no evidence of viable cancer cells. In the 
present study patients with grades 3 and 2 were classified into the sensitive group, while 
those with grades 1 and 0 were classified into the resistant group.  
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RNA isolation 
 
Cells were treated with the QIAzol Lysis Reagent (QIAGEN, Venlo, NED) in accordance 
with the manufacturer’s instructions for total-RNA extraction. The concentration and 
purity of extracted RNA was evaluated using a NanoDrop Lite Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). 
 
Quantitative reverse-transcription-PCR (qRT-PCR) 
 
Total RNA was converted to cDNA using a QuantiTect Reverse Transcription Kit 
(QIAGEN). Real-time PCR was performed in triplicate using QuantiTect SYBR® Green 
PCR Kits (QIAGEN) and a MyiQTM2 Two-Color Real-Time PCR Detection System (Bio-
Rad, Hercules, CA, USA) in accordance with the manufacturer’s protocol. The primers 
for ZNF750 (Assay name: Hs_ZNF750_1_SG) and glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) (Assay name: Hs_GAPDH_1_SG) as an internal control, 
which had been obtained from QIAGEN, were used. 
 
Transfection of small interfering RNAs (siRNAs) 
 
The small interfering RNAs (siRNAs) (3 unique 27mer siRNA duplexes; ZNF750 Cat. 
No. SR3125578; Origene Technologies, Rockville, MD, USA) and negative control 
siRNA (Universal scrambled negative control siRNA duplex; Cat. No. SR30004, Origene 
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Technologies) were transfected using the LipofectamineTM RNAiMAX Transfection 
Reagent (Thermo Fisher Scientific) in accordance with the manufacturer’s protocol. 
 
Cell proliferation, migration and invasion assays 
 
Following the transfection of siZNF750 or the negative control, proliferation, migration 
and invasion assays were performed in accordance with the previously reported protocol 
[15].  
In brief, cells were seeded in 96-well plates at 5 × 103 cells per well in 100 μl of medium 
containing 10% FBS. After 72 h, the cell proliferation was evaluated using the Cell 
Counting Kit-8 (Dojindo, Kumamoto, Japan). In each treatment group, triplicate wells 
were assessed for cell viability. Cell motility was evaluated using a micropore chamber 
assay. Cell migration was assessed using a 24-well micropore transparent PET membrane 
with 8.0-μm pores (BD Biosciences, Bedford, MA, USA), and cell invasion was assessed 
using a 24-well Matrigel-coated micropore membrane with 8.0-μm pores (BD 
Biosciences). Cell migration/invasion was evaluated by counting the number of cells that 
had migrated/invaded through the membrane. 
 
Apoptosis detection 
 
Apoptosis detection was performed using terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) staining with the In situ Apoptosis Detection 
Kit (MK500, Takara Bio Inc., Shiga, Japan) after the transfection of siZNF750 or the 
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negative control. TUNEL-positive cells were quantified through manual counting in 
random microscopic fields. 
  
Statistical analyses 
 
The correlation between the groups was assessed using Fisher’s exact test. The survival 
rates were assessed using the Kaplan-Meier method and the log-rank test. A Cox 
proportional hazards model was performed to evaluate the significance of ZNF750 
expression as a prognostic factor. A univariate analysis was performed to calculate the 
odds ratios (ORs) and 95% confidence intervals (CIs). A multiple logistic regression 
analysis was performed to evaluate the factors that predict CRT sensitivity. The 
correlation between two variables and numerical values was assessed using Wilcoxon’s 
rank sum test or t-test. The JMP version 12 software program (SAS Institute Inc., Cary, 
NC, USA) was used for all statistical analyses, and statistical significance was defined 
as a P values <0.05. 
 
Results  
 
Relationship between the ZNF750 expression and clinicopathological features 
 
Among 124 cases, 73 (58.9%) had tumors with low ZNF750 expression, and 51 (41.1%) 
had tumors with high ZNF750 expression.  
A low expression of ZNF750 was associated with positive lymph node metastasis (P = 
0.028). No significant relationship was observed between the expression of ZNF750 and 
other clinicopathological factors, such as age, sex, tumor depth, stage, and tumor 
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differentiation. However, the proportions of advanced tumor depth, advanced stage, and 
moderate to poorly-differentiated tumor tended to be higher in the low-expression group 
(Table 3). 
 
Table 3. Relation Between ZNF750 Expression and  
Clinicopathological Characteristics 
Characteristics ZNF750 Expression P value 
 low high  
Age    
  ≤65 years 40 25 0.586 
  >65 years 33 26  
Sex    
  Male 59 44 0.475 
  Female 14 7  
Tumor depth    
  Tis/T1 30 24 0.582 
  T2/T3/T4 43 27  
LN status    
  N0 30 32 0.028 
  N1 43 19  
Stage    
  0/I 39 35 0.098 
  II/III/IV 34 16  
Tumor Differentiation    
  Well 18 15 0.797 
  Moderate 43 27  
  Poor 12 9  
 
 
Correlation between the prognosis and ZNF750 expression and the histopathological 
features 
 
A survival analysis using the Kaplan-Meier method and the log-rank test showed that a 
low ZNF750 expression was associated with a significantly poorer OS than a higher 
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expression (5-year survival rate: low/high = 45.6%/60.9%, P = 0.044) (Fig. 3). A 
univariate analysis showed that a deeper T stage, positive lymph node metastasis, 
advanced stage, and low ZNF750 expression were significant prognostic factors. A 
multivariate analysis revealed that a low ZNF750 expression was an independent 
prognostic factor for the OS in ESCC patients (hazard ratio, 1.922; 95% confidence 
interval, 1.123-3.389; P = 0.020) (Table 4). 
 
 
Figure 3. A comparison of the overall survival of high and low ZNF750 expression 
groups of ESCC patients. 
 
Table 4. Univariate and Multivariate Analysis of Clinicopathological 
factors and Overall Survival in ESCC 
Factors Univariate analysis Multivariate analysis 
 P value Hazard Ratio (95% CI) P value 
Age ≥65 years 0.097 1.678 (0.990-2.868) 0.055 
Male 0.157 1.628 (0.783-3.961) 0.232 
T2/T3/T4 <0.001 1.865 (0.962-3.736) 0.071 
N1 0.002 0.914 (0.363-2.260) 0.848 
Stage II/III/IV <0.001 2.181 (0.799-6.059) 0.132 
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Poor differentiation 0.295 1.170 (0.587-2.160) 0.633 
Low ZNF750 expression 0.040 1.922 (1.123-3.389) 0.020 
CI, confidence interval 
 
The relationship between the ZNF750 expression and the pathological efficacy of CRT 
 
The pathological efficacy of CRT is shown in Table 2. Fifteen (17.2%) patients were 
classified as Grade 3, 41 (47.1%) patients were classified as grade 2, and 31 (35.7%) 
patients were classified as grade 1/0. Among the 87 cases, the expression of ZNF750 
was high in the tumors of 20 (23%) patients, intermediate in the tumors of 29 (33%) 
patients, and low in the tumors of 38 (44%) patients. Furthermore, in 80% of the tumors 
in which the expression of ZNF750 was high, 76% of the tumors in which the 
expression of ZNF750 was intermediate and 47% of the tumors in which the expression 
of ZNF750 was low, showed good CRT sensitivity (grades 3 and 2). Fisher’s exact test 
revealed a statistically significant difference between the ZNF750 expression and the 
histopathological efficacy (P = 0.016). Furthermore, there was an intimate relationship 
between the ZNF750 expression and the CRT sensitivity (Kendall’s τb = 0.2846, P = 
0.005). In other words, the high expression of ZNF750 was associated with good 
sensitivity to CRT, whereas the low expression of ZNF750 was associated with 
resistance to CRT. Thus, this result suggested that the expression of ZNF750 may 
predict a better response to CRT in ESCC (Table 5). 
 
Table 5. Relationship between ZNF750 expression and 
pathologic efficacy of CRT 
Expression level Grade 3/2 Grade 1/0 Total P value 
Low (<30) 18 (47%) 20 (53%) 38 (100%) 
0.016* 
Intermediate (≥30, <60) 22 (76%) 7 (24%) 29 (100%) 
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High (≥60) 16 (80%) 4 (20%) 20 (100%) 
* Fisher’s exact test (Kendall’s τb = 0.2846, P = 0.005) 
 
The univariate analysis of the factors predicting sensitivity to CRT 
 
We divided the ZNF750 expression into two levels: low (<30%) and intermediate-to-
high (≥30%) and performed a univariate analysis to compare the ZNF750 expression 
and various clinicopathological elements to investigate the validity of predictive 
biomarkers for CRT sensitivity. Only the expression of ZNF750 was significantly 
associated with CRT sensitivity (OR, 3.838; 95% CI, 1.522-9.681; P = 0.006), 
indicating that the intermediate-to-high expression of ZNF750 may be a predictive 
factor that is associated with the response to CRT (Table 6). 
 
Table 6. Univariate analysis of Predicting Factors of Sensitivity to CRT 
Factors Groups Total Grade 3/2 Grade 1/0 OR 95% CI P value 
Age ≤60 17 13 (76%) 4 (24%) 2.040 0.603-6.910 0.277 
 >60 70 43 (61%) 27 (39%)    
Sex M 77 49 (64%) 28 (36%) 1.333 0.319-5.572 1.000 
 F 10 7 (70%) 3 (30%)    
Tumor depth T1, T2 8 6 (75%) 2 (25%) 1.740 0.329-9.192 0.706 
 T3, T4 79 50 (63%) 29 (37%)    
Tumor size <10 74 49 (66%) 25 (34%) 1.680 0.510-5.534 0.531 
 ≥10 13 7 (54%) 6 (46%)    
LN status N0 6 4 (67%) 2 (33%) 1.115 0.192-6.464 1.000 
 N1 81 52 (64%) 29 (36%)    
Stage I, II 8 6 (75%) 2 (25%) 1.740 0.329-9.192 0.706 
 III, IV 79 50 (63%) 29 (37%)    
Tumor Differentiation Well/Moderate 52 29 (56%) 23 (44%) 1.700 0.594-4.861 0.438 
 Poor 22 15 (68%) 7 (32%)    
Total dose of Radiation ≤40 69 43 (62%) 26 (38%) 1.572 0.503-4.918 0.583 
 >40 18 13 (72%) 5 (28%)    
Total dose of 5-FU ≤4000 67 43 (64%) 24 (36%) 1.037 0.364-2.950 1.000 
 >4000 20 13 (65%) 7 (35%)    
Total dose of CDDP ≤100 54 36 (67%) 18 (33%) 1.300 0.529-3.193 0.647 
 >100 33 20 (61%) 13 (39%)    
ZNF750 expression <30 38 18 (47%) 20 (53%) 3.838 1.522-9.681 0.006 
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  ≥30 49 38 (78%) 11 (22%)       
OR, odds ratio; CI, confidence interval 
 
The multivariate analysis of factors predicting sensitivity to CRT 
 
We performed a multivariate logistic regression analysis to investigate the effects of 
various factors on sensitivity to CRT. We chose the following elements: age, tumor depth, 
tumor size, stage, tumor differentiation, total dose of radiation and CDDP, which showed 
relatively high levels of significance in the univariate analysis (Table 6). The tumor size 
(<10 cm), poor differentiation, and the total dose of radiation (>40 Gy) showed a slight 
relationship with good CRT sensitivity, however, this trend was not statistically 
significant. On the other hand, the intermediate-to-high expression of ZNF750 (≥30%) 
was found to be an independent predictive factor for CRT sensitivity (OR, 3.059; 95% CI, 
1.096-8.937; P = 0.033; Table 7). 
 
Table 7. Multivariate Analysis of Independent Predicting  
Factors for CRT Sensitivity 
Factors OR 95% CI 
P 
value 
Age ≤60 years 1.315 0.330-5.878 0.701 
Tumor depth T1, T2 1.615 0.034-101.591 0.799 
Tumor size <10 cm 2.222 0.531-9.966 0.274 
Stage I, II 1.598 0.056-45.485 0.756 
Poor differentiation 2.034 0.606-7.365 0.253 
Total dose of radiation >40 Gy 2.431 0.663-10.109 0.183 
Total dose of CDDP ≤100 mg 1.284 0.431-3.862 0.652 
ZNF750 expression ≥30 % 3.059 1.096-8.937 0.033 
OR, odds ratio; CI, confidence interval 
 
The evaluation of the effect of ZNF750 knockdown on proliferation, migration, invasion, 
and apoptosis in ESCC cell lines 
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The expression of ZNF750 was assessed in ESCC cell lines using TE8 and TE11. After 
siZNF750 transfection into the both cell lines, we confirmed that the levels of ZNF750 
mRNA were noticeably decreased (3.4% ± 0.8%, P = 0.001 and 4.5% ± 0.5%, P = 0.010 
of control in TE8 cells; 0.8% ± 0.4%, P = 0.008 and 1.2% ± 0.4%, P = 0.034 in TE11 
cells) (Fig. 4A). The proliferation assay showed that cell growth was significantly 
increased by the transfection of siZNF70 in both cell lines (127% ± 3.4%, P = 0.0495 
and 160% ± 3.0%, P = 0.0495 of control in TE8 cells; 150% ± 2.1%, P = 0.0495 and 
136% ± 3.0%, P = 0.0495 in TE11 cells) (Fig. 4B). In the migration assay, there were 
significant differences in the acceleration of cell motility between the siZNF750 
transfected cells and control cells (305% ± 117.0%, P = 0.021 and 240% ± 43.2%, P = 
0.021 of control in TE8 cells; 192% ± 22.9%, P = 0.021 and 204% ± 8.9%, P = 0.021 in 
TE11 cells) (Fig. 4C). Similarly, the invasion assay revealed that the cell invasion was 
significantly higher in the siZNF750 transfectants than in the control transfectant (218% 
± 42.9%, P = 0.021 and 300% ± 34.8%, P = 0.021 of control in TE8 cells; 267% ± 
53.3%, P = 0.021 and 247% ± 85.4%, P = 0.021 in TE11 cells) (Fig. 4C). In addition, 
the apoptosis assay showed that the apoptotic cells were significantly decreased by the 
transfection of siZNF750 in both cell lines (33.3% ± 11.2%, P = 0.019 and 15.6% ± 
8.5%, P = 0.019 of control in TE8 cells; 16.1% ± 6.5%, P = 0.018 and 38.7% ± 10.5%, P 
= 0.020 in TE11 cells) (Fig. 4D). 
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Figure 4. The effects of ZNF750 knockdown on ESCC cell proliferation, migration, 
invasion and apoptosis. ESCC cell lines (TE8 and TE11) were transfected with control 
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siRNA or two siRNAs (siZNF750-1 and siZNF750-2). (A) ZNF750 expression in 
ESCC cell lines after transfection of siZNF750. (B) Results of the proliferation assay. 
(C) Results of the migration/invasion assay. (D) Results of the apoptosis assay. * P < 
0.05. 
 
Discussion  
 
The purpose of the present study was to clarify the clinicopathological features, their 
significance as prognostic factors of ZNF750 expression, and the correlation between the 
ZNF750 expression and the effectiveness of CRT in ESCC. In this study, a low ZNF750 
expression had a significant correlation with positive lymph node metastasis (P = 0.028). 
Furthermore, there was a significant relationship between the low expression of ZNF750 
in ESCC and a poor OS (hazard ratio, 1.922; 95% confidence interval, 1.123-3.389; P = 
0.020). We also demonstrated that siZNF750 significantly increased the cell proliferation, 
migration, and invasion and decreased apoptosis. These results suggest that ZNF750 is a 
suppressor of tumor progression and that the expression of ZNF750 may be a novel 
candidate prognostic biomarker for ESCC patients. Furthermore, the present results 
showed an intimate correlation between the ZNF750 expression and the efficacy of CRT 
(Kendall’s τb = 0.2846, P = 0.005). The high and intermediate expression of ZNF750 
suggested a good response to CRT (78% Grade 3/2). In contrast, the low expression of 
ZNF750 suggested low sensitivity to CRT (53% Grade 1/0). Although there are few valid 
biomarkers that can be used to predict the sensitivity to CRT at present, these results 
suggest that the ZNF750 expression may be a candidate biomarker for predicting the 
effectiveness of CRT (OR, 3.059; 95% CI, 1.096-8.937; P = 0.033). 
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Several reports have shown that the expression of ZNF750 is decreased in cancer tissues 
compared with normal tissues [5, 6, 10], and the mutation of ZNF750 inhibited the 
activation of differentiation genes and caused functional deterioration [9, 16]. Some 
studies have shown that the decreased expression of ZNF750 promoted cell growth, 
migration, and invasion in squamous cell carcinoma [5, 6, 10], and Cohen et al. revealed 
that the down-regulation of ZNF750 decreased apoptosis in human keratinocytes [17]. 
The present study showed the same results in cell line experiments. This suggests that 
ZNF750 is involved in suppressing tumor development in ESCC. In addition, Hazawa et 
al. reported that the low expression of ZNF750 correlated with a poor prognosis in head 
and neck squamous cell carcinoma and lung squamous cell carcinoma [10], and we 
reported this value to be a prognostic factor of ZNF750 in ESCC for the first time. 
 
Differentiation abnormalities play an important role in tumorigenesis. Recent studies have 
revealed that differentiation-related genes are associated with many cancers [18-21], 
including ESCC [22-26]. Therefore, dysfunction of genes regulating differentiation has a 
relationship with tumor development in ESCC. For example, KLF4, a transcriptional 
factor containing zinc finger, has been shown to play an essential role in cell 
differentiation and proliferation [23, 27-29]. It was recently reported that KLF4 was a 
tumor suppressor and prognostic biomarker in ESCC patients [30]. In addition, Zhang et 
al. showed that KLF4 inhibits the regulation of the epithelial-mesenchymal transition 
(EMT) and has a relationship with cisplatin resistance [31]. Several reports have shown 
that ZNF750, an essential transcriptional regulator of epidermal differentiation, positively 
regulates KLF4 expression [9, 10, 16]. In other words, ZNF750 is associated with KLF4, 
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a tumor suppressor gene, and is considered to have an important role in treatment 
resistance. Indeed, we revealed that a low ZNF750 expression was associated with poor 
sensitivity to chemoradiotherapy. In addition, Hu et al. revealed that the upregulation of 
KLF4 by methylseleninic acid could inhibit cell growth in ESCC cells [32]. These 
findings suggest that the upregulation of ZNF750 may be an effective treatment strategy 
for ESCC patients. 
 
In conclusion, we herein demonstrated that the low expression of ZNF750 correlates 
with positive lymph node metastasis, a poor OS, and a low sensitivity to CRT in patients 
with ESCC. Furthermore, the downregulating of ZNF750 increased the cell growth, 
migration, and invasion and decreased apoptosis in ESCC cell lines. These findings 
suggest that ZNF750 may be a useful novel prognostic biomarker and a clinically 
feasible biomarker of CRT sensitivity, and that the regulation of ZNF750 may become 
an important target in the treatment of ESCC. 
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